EMA Recommendations To Minimize Risks With SGLT2 And Tysabri
This article was originally published in Scrip
The European Medicines Agency has confirmed the recommendations of its Pharmacovigilance Risk Assessment Committee (PRAC) to update the product information for the sodium-glucose co-transporter-2 (SGLT2) inhibitors, used to treat type 2 diabetes, to include diabetic ketoacidosis as a rare adverse reaction. The EMA has also recommended temporarily stopping SGLT2-inhibitor use in patients who are in hospital because of serious illness or are undergoing major surgery.
Register for our free email digests: